Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806591 | 0.90 | KDM4E (0.60) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL1806122 | 0.88 | PDE4B (0.54) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL1809388 | 0.86 | KMT2A (0.58) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL1805898 | 0.86 | HSD11B1 (0.60) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL1807918 | 0.86 | MGLL (0.54) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL1808347 | 0.84 | MGLL (0.53) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL1809057 | 0.84 | MGLL (0.73) | MGLLKMT2AMEN1HRH3 | |
| SCHEMBL1808791 | 0.83 | MGLL (0.53) | MGLLKMT2AMEN1HRH3PDE4B | |
| SCHEMBL12188726 | 0.82 | MGLL (0.67) | MGLLKMT2AMEN1HRH3 | |
| SCHEMBL1806630 | 0.82 | HRH3 (0.64) | MGLLKMT2AMEN1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | MGLL 4513/4885KMT2A 1032/4885MEN1 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.